Interleukin-12 as an in situ cancer vaccine component: a review Emily M. ChengNoah W. TsarovskyAlexander L. Rakhmilevich Review Article 13 January 2022 Pages: 2057 - 2065
PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression A. FilipponeM. LanzaI. Paterniti Review Article Open access 29 January 2022 Pages: 2067 - 2075
Adoptive cell therapies in thoracic malignancies Julie LasvergnasMarie NaigeonBoris Duchemann Review Article 07 February 2022 Pages: 2077 - 2098
Antibody-dependent cellular phagocytosis of tropomyosin receptor kinase C (TrkC) expressing cancer cells for targeted immunotherapy Phei San LaiSyed Muhammad UsamaChin Siang Kue Original Article 15 January 2022 Pages: 2099 - 2108
Pre-treatment serum protein levels predict survival of non-small cell lung cancer patients without durable clinical benefit by PD-1/L1 inhibitors Yuhei HarutaniYuichi OzawaNobuyuki Yamamoto Original Article 16 January 2022 Pages: 2109 - 2116
Immune inactivation by neuropilin-1 predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer Yanze YuHan ZengZewei Wang Original Article 18 January 2022 Pages: 2117 - 2126
Naringenin potentiates anti-tumor immunity against oral cancer by inducing lymph node CD169-positive macrophage activation and cytotoxic T cell infiltration Sho KawaguchiKenta KawaharaHideki Nakayama Original Article Open access 19 January 2022 Pages: 2127 - 2139
Inflammasome activation, NLRP3 engagement and macrophage recruitment to tumor microenvironment are all required for Salmonella antitumor effect Amy MónacoSofía ChilibrosteMaría Moreno Original Article 21 January 2022 Pages: 2141 - 2150
The multitargeted receptor tyrosine kinase inhibitor sunitinib induces resistance of HER2 positive breast cancer cells to trastuzumab-mediated ADCC Eliza GutiZsolt RegdonLászló Virág Original Article Open access 23 January 2022 Pages: 2151 - 2168
Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors Mitchell S. von ItzsteinAmrit S. GonuguntaDavid E. Gerber Original Article Open access 24 January 2022 Pages: 2169 - 2181
Correction to: Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors Mitchell S. von ItzsteinAmrit S. GonuguntaDavid E. Gerber Correction Open access 21 May 2022 Pages: 2183 - 2184
Single-cell transcriptome profiling reveals intra-tumoral heterogeneity in human chordomas Wanru DuanBoyan ZhangZan Chen Original Article 27 January 2022 Pages: 2185 - 2195
Enhancing the anti-leukemia immunity of acute lymphocytic leukemia-derived exosome-based vaccine by downregulation of PD-L1 expression Fang HuangZhichao LiSiguo Hao Original Article 29 January 2022 Pages: 2197 - 2212
Targeting transforming growth factor-β2 by antisense oligodeoxynucleotide accelerates T cell-mediated tumor rejection in a humanized mouse model of triple-negative breast cancer Hong Kyu LeeHyeong-Jin JiKyung-Chul Choi Original Article 31 January 2022 Pages: 2213 - 2226
Comparison of characteristics and tumor targeting properties of extracellular vesicles derived from primary NK cells or NK-cell lines stimulated with IL-15 or IL-12/15/18 Miriam AarsundFilip M. SegersMarit Inngjerdingen Original Article Open access 04 February 2022 Pages: 2227 - 2238
Severe immune-related adverse events of immune checkpoint inhibitors for advanced non-small cell lung cancer: a network meta-analysis of randomized clinical trials Jingjing GuLei ShiWeidong Zhang Original Article 06 February 2022 Pages: 2239 - 2254
Murine myeloid derived suppressor cells possess a range of suppressive mechanisms—Granzyme B is not among them Ellis TibbsXuefang Cao Original Article 07 February 2022 Pages: 2255 - 2266
GM-CSF elicits antibodies to tumor-associated proteins when used as a prostate cancer vaccine adjuvant Hemanth K. PotluriTun L. NgDouglas G. McNeel Original Article 08 February 2022 Pages: 2267 - 2275
Phase I study of expanded natural killer cells in combination with cetuximab for recurrent/metastatic nasopharyngeal carcinoma Chwee Ming LimAnthony LiouNoriko Shimasaki Clinical Trial Report 30 January 2022 Pages: 2277 - 2286
Pancreatic cancer survival prediction via inflammatory serum markers Mira LankiHanna SeppänenCaj Haglund Research Report Open access 16 January 2022 Pages: 2287 - 2292
Immune escape mechanism behind resistance to anti-PD-1 therapy in gastrointestinal tract metastasis in malignant melanoma patients with multiple metastases Misato ItoKosaku MimuraKoji Kono Research Report 30 January 2022 Pages: 2293 - 2300